Key Patent of Protagen Granted in Japan
Protagen is the exclusive licensee of the Max-Planck Society to commercialize the UNIclone® technology platform which serves the needs of modern proteomic analysis, to support in-vitro and companion diagnostic R&D projects (UNIarray®), and to provide antibody profiling tools (UNIchip®) for faster selection of therapeutic antibodies. One of the world largest selection of human recombinant proteins expressed in E.coli represents more than 10,000 human genes, and is in the possession of Protagen. For the full exploitation of this unique platform, Protagen has developed a proprietary high-throughput workflow for production and application of protein microarrays.
“This notice of allowance further strengthens our leading position in the area of protein arrays and diagnostic marker discovery in general. In particular, it supports our leading position in the determination of indication-specific autoantibody patterns for the development of novel serum based in-vitro diagnostics”, underscores Dr. Stefan Müllner, Chief Executive Officer of Protagen.
The technology is currently successfully used in the internal research and development programs for early detection and diagnosis of cancer, auto-immune and neurological diseases as well as in cooperation with biopharmaceutical companies worldwide.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous